Recovery and assessment timescales in rheumatoid arthritis extend over weeks to months. Initial inflammatory responses to infusion typically resolve within 1–2 weeks. Meaningful reduction in joint swelling, pain, and function usually requires 4–12 weeks to become apparent. Disease Activity Score (DAS28) is typically reassessed at 6, 12, and 24 weeks post-infusion to document response. Many patients experience gradual improvement rather than dramatic recovery. Continued monitoring for adverse effects proceeds for 12 months minimum. Patients should not expect immediate pain relief or mobility gain; gradual modulation of immune activity is the biological mechanism, not acute anti-inflammatory surge.
Clinical evidence in rheumatoid arthritis shows encouraging preliminary signals. Seven recruiting trials indicate sustained clinical interest and patient demand. Published trials have documented reductions in serum inflammatory markers (IL-6, TNF-α) and improvements in Disease Activity Score (DAS28) following MSC infusion, with some patients achieving low-disease-activity remission. However, many studies are small and uncontrolled, lacking the rigorous blinding and long-term follow-up expected of modern rheumatology trials. Comparisons with established DMARDs (disease-modifying antirheumatic drugs) are sparse; MSCs may complement rather than replace conventional immunosuppression. Relapse following initial improvement occurs in a proportion of participants, particularly when conventional therapy is withdrawn.
Am I a candidate? → · Rheumatoid Arthritis: full overview → · Rheumatoid Arthritis cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite